Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 20INDUSTRY 13NIH 8NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Glioma 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 44Vincristine 37Radiotherapy 30Radiation 30Cisplatin 30Carboplatin 29Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Platinum 15Gemcitabine 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 141,2-diaminocyclohexaneplatinum II citrate 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × dabrafenib × 1 year × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pediatric Brain Tumor Consortium

Phase 1/2 Active not recruiting
57 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡